# High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

> **NCT03945591** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 23 (actual)

## Conditions studied

- GVHD

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03945591
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-20
- **Primary completion:** 2022-12-29
- **Final completion:** 2024-01-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945591, "High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03945591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*